Treatment to protect mitochondria may enter clinical trials this year
An experimental therapy called ASHA-091, which was seen to restore normal mitochondria function and possibly be disease modifying…
Articles by Andrea Lobo
Risvodetinib shows potential to slow disease progression in clinical trial
Risvodetinib, an oral therapy being developed by Inhibikase Therapeutics for Parkinson’s disease, appears to stabilize disease status…
Bemdaneprocel still shows benefits 1.5 years after treatment in trial
Use of bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell-based therapy, was found to be safe and well tolerated among people…
bit.bio, MJFF to develop human cell products for research in Parkinson’s
bit.bio and The Michael J. Fox Foundation (MJFF) are teaming up in a multiyear effort to develop a range of…
Parkinson’s clinical trial of ALX-001 DMT to start by month’s end
Allyx Therapeutics said it will begin a clinical trial by the end of the month to test its lead…
New TrialPioneer online tool can help companies explore trial designs
A newly launched online tool called TrialPioneer, which makes use of artificial intelligence (AI), aims to help pharmaceutical and…
NE3107 added to levodopa enhances motor, non-motor benefits
Adding NE3107 to standard carbidopa/levodopa (CD/LD) therapy eases motor and non-motor symptoms in people with Parkinson’s disease, according to data…
Zambon gains exclusive rights to oral therapy IPX203 in Europe
Zambon Biotech has entered into an exclusive deal with Amneal Pharmaceuticals for rights to seek approval and commercialize…
Metabolite of cancer medication shows promise for Parkinson’s
A metabolite called M324 of the cancer medicine rucaparib is able to reduce the abnormal accumulation of alpha-synuclein protein in…
Grant will advance VNA-318 for Parkinson’s, age-related diseases
The Swiss company Vandria has been awarded a multimillion-dollar research grant to help advance the development of VNA-318, its…